Navigation Links
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
Date:9/9/2011

Nektar using its polymer conjugate technology platform.  NKTR-102 has been evaluated in two separate Phase 2 studies for the treatment of platinum-refractory/resistant ovarian cancer and metastatic breast cancer patients.  In addition, NKTR-102 is also being tested as a single agent in a Phase 2 clinical trial in patients with second-line colorectal cancer and a Phase 1 clinical trial evaluating NKTR-102 in combination with 5-FU therapy.  

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Vermillion, Inc. (NASDAQ: VRML ... and women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record ... for laboratory services companies. She has more than 20 ... where she held the position of Director, Lab Services ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Development, LLC (JRD) announced today that the U.S. Food ... designation to the supplemental New Drug Application (sNDA) filed ... an oral anticoagulant, to reduce the risk of thrombotic ... The FDA grants Priority Review to medicines ...
... Feb. 27, 2012 With cold and flu season ... American Pharmacists Association (APhA) encourages patients to actively ... medications. Pharmacists are the most accessible health care provider ... best over-the-counter (OTC) medication for cold, flu and allergy ...
Cached Medicine Technology:U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Market Research “Home Audio Equipment (Product Types - Home ... audio accessories) Market - Global Industry Analysis, Size, Share, ... was valued at USD 15.94 billion in 2012 and ... growing at a CAGR of 3.7% from 2013 to ...
(Date:8/21/2014)... 21, 2014 The Swedish-American Life ... conference will focus on the Future of Medicine ... innovation and commercialization. , With the mission to ... the worlds' of business and science. "Over the ... Summit, gathering a diverse community with representatives challenging ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... using sunscreen dropped nearly 12 percent in the last decade, ... the number of teens using indoor tanning beds barely decreased. ... risk of skin cancers, including deadly melanomas, the researchers noted. ... of teens who reported wearing sunscreen, from 67.7 percent in ...
(Date:8/21/2014)... August 21, 2014 The Onder Law ... product liability law, announces the launch of a new ... information on morcellator surgery lawsuits for cancer ... morcellator cancer warning and the July 2014 morcellator recall. ... April 17, 2014 FDA warning on morcellator surgery and ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... reporting successful application of the technology used in home ... make anticancer drugs like tamoxifen and paclitaxel dissolve more ... the disease. The process, described in ACS, journal, Langmuir, ... has potential for improving the performance of dyes, paints, ...
... PITTSBURGHUniversity of Pittsburgh researchers have recorded neuron activity ... biological root of the teenage propensity to consider ... more vulnerable to drug addiction, behavioral disorders, and ... the Journal of Neuroscience that electrode ...
... low socioeconomic status (SES) is associated with higher ... arthritis (RA). Statistically significant differences in race, public ... between depressed and non-depressed patients. Study findings are ... Care & Research , a journal published by ...
... 26 (HealthDay News) -- Hispanic seniors in the United ... be vaccinated against flu and pneumonia, a new study ... analyzed data from more than 244,000 seniors who took ... lifetime immunization rates for pneumonia were 74 percent for ...
... Staphylococcus aureus , the bacterium which is responsible for ... a strategy of hiding within host cells to escape ... The research, published by EMBO Molecular Medicine , ... their environmental conditions, lie dormant inside host cells and ...
... to 20 per cent of nurses and nursing students may ... tackling this difficult issue - and protecting public safety - ... message in a paper in the February issue of the ... recommended six key points that could be built into alternative-to-dismissal ...
Cached Medicine News:Health News:Pitt team finds teen brains over-process rewards, suggesting root of risky behavior, mental ills 2Health News:Low socioeconomic status increases depression risk in rheumatoid arthritis patients 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 3
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i...
Tibial distractor...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Medicine Products: